Alnylam Pharmaceuticals (ALNY) Stock Analysis

November 11, 2026

This is a peer-relative look at Alnylam Pharmaceuticals (ALNY): its performance, risk, profitability, growth, financial strength, dividend, and valuation are each measured against its Pharmaceuticals, Biotechnology & Life Sciences peers, so every number reads in context rather than in isolation.

Company Profile

Company profile fields for Alnylam Pharmaceuticals (ALNY)
Profile Item	ALNY
Name	Alnylam Pharmaceuticals, Inc.
Country/Region	United States
GICS Sector	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology
GICS Sub-Industry	Biotechnology
Market Capitalization	20.89 billion USD
Currency	USD
Exchange	Nasdaq
Listing Date	June 1, 2004
Security Type	Common Stock

Price Performance

Cumulative Growth

ALNY

GSPC

Alnylam Pharmaceuticals (ALNY) vs. S&P 500 (GSPC): Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Alnylam Pharmaceuticals (ALNY) and S&P 500 (GSPC). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Alnylam Pharmaceuticals (ALNY) and S&P 500 (GSPC). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Alnylam Pharmaceuticals (ALNY) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: ALNY	Industry group median
Total Return (1Y)	-64.57%	24.62%
Total Return (3Y, Annualized)	-1.58%	20.37%
Total Return (5Y, Annualized)	-3.13%	-4.02%

Risk Profile

Drawdown History

ALNY

GSPC

Alnylam Pharmaceuticals (ALNY) vs. S&P 500 (GSPC): Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Alnylam Pharmaceuticals (ALNY) and S&P 500 (GSPC). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Alnylam Pharmaceuticals (ALNY) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: ALNY	Industry group median
Volatility (1Y, Annualized)	54.08%	66.36%
Beta (5Y)	0.45	0.93
Max Drawdown (5Y)	-68.25%	-80.19%

Risk-Adjusted Performance

Risk-Return Positioning

Each dot is a stock plotted by 1-year volatility (risk) and 1-year return. ALNY is highlighted; the dashed line is the Capital Allocation Line from the risk-free rate through the industry median — dots above it are stronger on a risk-adjusted basis.

Risk-Adjusted Metrics

Alnylam Pharmaceuticals (ALNY) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: ALNY	Industry group median
Sharpe Ratio (1Y)	-1.27	0.36
Sortino Ratio (1Y)	-1.45	0.58

Profitability

ROE (TTM)

Alnylam Pharmaceuticals (ALNY) posts ROE of 138.07%, above the industry benchmark range. Equity is being turned into profit at an exceptional rate, but very high ROE should still be checked against leverage, buybacks, and the size of the equity base.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

138.07%

Group distribution

ALNY: 138.07%
Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Largest peers

ALNY: 138.07%
LLY: 86.02%
NVS: 24.33%
AZN: 22.57%
JNJ: 20.02%
MRK: 5.06%
ABBV: --

Where Alnylam Pharmaceuticals (ALNY) stands on ROE within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Net Margin (TTM)

Alnylam Pharmaceuticals (ALNY) keeps 52.85% of revenue as net profit on net margin, above the industry benchmark range. That is unusually strong bottom-line conversion, though tax effects, asset sales, or other one-off gains should be checked before treating it as durable.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

52.85%

Group distribution

ALNY: 52.85%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Largest peers

ALNY: 52.85%
LLY: 31.90%
AZN: 17.68%
NVS: 17.49%
JNJ: 16.20%
ABBV: 15.67%
MRK: 3.64%

Where Alnylam Pharmaceuticals (ALNY) stands on net margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Operating Margin (TTM)

Alnylam Pharmaceuticals (ALNY) turns 23.72% of revenue into operating profit, putting operating margin in the upper peer quartile. Before financing and taxes enter the picture, the day-to-day business keeps more of each sales dollar than most industry peers.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.72%

Group distribution

Max: 83.12%
ALNY: 23.72%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Largest peers

LLY: 53.66%
ABBV: 39.59%
MRK: 35.22%
NVS: 34.27%
AZN: 29.57%
JNJ: 25.74%
ALNY: 23.72%

Where Alnylam Pharmaceuticals (ALNY) stands on operating margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Profitability Metrics

Alnylam Pharmaceuticals (ALNY) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: ALNY	Industry group median
ROE (TTM)	138.07%	-26.66%
ROA (TTM)	9.51%	-12.50%
Net Margin (TTM)	52.85%	0.00%
Operating Margin (TTM)	23.72%	0.00%
Gross Margin (TTM)	77.28%	37.87%

Growth

Revenue Growth

Alnylam Pharmaceuticals (ALNY) grew revenue 65.19%, in the upper peer quartile. The top line is expanding faster than at most industry peers, which points to share gains or stronger pricing.

Alnylam Pharmaceuticals (ALNY): Revenue Growth across different time periods, set against Pharmaceuticals, Biotechnology & Life Sciences industry-group medians.

EPS Growth

No usable EPS growth is available for Alnylam Pharmaceuticals (ALNY) this period, so the earnings-momentum read is skipped.

Alnylam Pharmaceuticals (ALNY) doesn't report EPS Growth this period; the bars show the Pharmaceuticals, Biotechnology & Life Sciences industry-group medians on their own.

Growth Metrics

Alnylam Pharmaceuticals (ALNY) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: ALNY	Industry group median
Revenue Growth (YoY)	65.19%	11.45%
Revenue Growth (3Y CAGR)	52.98%	9.94%
EPS Growth (YoY)	--	4.28%
EPS Growth (3Y CAGR)	--	4.17%

Financial Strength

Current Ratio (MRQ)

Alnylam Pharmaceuticals (ALNY) has current ratio of 2.48, in the healthier middle range for its industry. The short-term asset cushion looks balanced relative to peers rather than stretched thin.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.48

Group distribution

Max: 25.13
Q3: 12.13
Median: 5.52
ALNY: 2.48
Q1: 2.47
Min: 0.10

Largest peers

ALNY: 2.48
LLY: 1.39
MRK: 1.35
JNJ: 1.02
AZN: 1.01
NVS: 0.88
ABBV: 0.87

Where Alnylam Pharmaceuticals (ALNY) stands on current ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Debt / Equity (MRQ)

Alnylam Pharmaceuticals (ALNY) has debt-to-equity ratio of 0.83, in the higher-leverage quartile for its industry. The heavier reliance on borrowing can make earnings, rates, or refinancing conditions matter more.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.83

Group distribution

Max: 1.42
ALNY: 0.83
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Largest peers

NVS: 1.29
LLY: 1.23
MRK: 1.20
ALNY: 0.83
AZN: 0.66
JNJ: 0.55
ABBV: --

Where Alnylam Pharmaceuticals (ALNY) stands on debt-to-equity ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Financial Strength Metrics

Alnylam Pharmaceuticals (ALNY) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: ALNY	Industry group median
Current Ratio (MRQ)	2.48	5.52
Debt / Equity (MRQ)	0.83	0.15
Net Debt / EBITDA	-0.57	1.08

Dividends

Dividend Yield (TTM)

Alnylam Pharmaceuticals (ALNY) pays no dividend, leaving dividend yield at 0.00% this period. Shareholders may still receive value through reinvestment or buybacks, but there is no dividend income to compare here.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Group distribution

ALNY: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Largest peers

NVS: 2.88%
ABBV: 2.40%
MRK: 2.29%
JNJ: 1.94%
AZN: 1.73%
LLY: 0.49%
ALNY: 0.00%

Where Alnylam Pharmaceuticals (ALNY) stands on dividend yield within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Payout Ratio (TTM)

Alnylam Pharmaceuticals (ALNY) paid no earnings out as dividends this period, leaving payout ratio at 0.00%. There is no dividend payout to size against earnings.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Group distribution

ALNY: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Largest peers

MRK: 343.43%
ABBV: 117.35%
NVS: 90.46%
JNJ: 80.12%
AZN: 45.38%
LLY: 21.71%
ALNY: 0.00%

Where Alnylam Pharmaceuticals (ALNY) stands on payout ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Metrics

Alnylam Pharmaceuticals (ALNY) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: ALNY	Industry group median
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

Alnylam Pharmaceuticals (ALNY) trades at P/E ratio of 7.88, in the cheaper earnings-multiple quartile for its industry. Investors are paying less for each dollar of TTM earnings than they usually pay for comparable businesses.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.88

Group distribution

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
ALNY: 7.88
Min: 0.07

Largest peers

MRK: 148.21
ABBV: 50.05
LLY: 43.95
JNJ: 41.92
NVS: 31.02
AZN: 26.37
ALNY: 7.88

Where Alnylam Pharmaceuticals (ALNY) stands on P/E ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

P/S Ratio (TTM)

Alnylam Pharmaceuticals (ALNY) trades at 4.17 on P/S ratio, roughly in the peer group’s normal range. The market is not making a strong cheap-or-rich statement about its revenue base.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.17

Group distribution

Max: 58.18
Q3: 25.77
Median: 7.30
ALNY: 4.17
Q1: 3.01
Min: 0.01

Largest peers

LLY: 13.95
ABBV: 7.80
JNJ: 6.69
MRK: 5.37
NVS: 5.35
AZN: 4.63
ALNY: 4.17

Where Alnylam Pharmaceuticals (ALNY) stands on P/S ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

P/B Ratio (MRQ)

Alnylam Pharmaceuticals (ALNY) trades at 5.79 on P/B ratio, roughly in line with the industry’s normal price-to-book range. Its balance sheet is not being priced at a clear discount or premium versus peers.

ALNY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.79

Group distribution

Max: 13.53
Q3: 6.54
ALNY: 5.79
Median: 3.25
Q1: 1.69
Min: -5.59

Largest peers

LLY: 29.96
NVS: 8.25
JNJ: 8.16
MRK: 8.06
ALNY: 5.79
AZN: 5.59
ABBV: -112.34

Where Alnylam Pharmaceuticals (ALNY) stands on P/B ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Valuation Metrics

Alnylam Pharmaceuticals (ALNY) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: ALNY	Industry group median
P/E Ratio (TTM)	7.88	26.69
P/S Ratio (TTM)	4.17	7.30
P/B Ratio (MRQ)	5.79	3.25
Free Cash Flow Yield (TTM)	1.57%	-1.66%